Department of Pathology, Second Hospital of Jilin University, Changchun, 130022, Jilin, China.
Department of Radiation Oncology, Second Hospital of Jilin University, Changchun, 130022, Jilin, China.
Mol Cell Biochem. 2021 Feb;476(2):757-765. doi: 10.1007/s11010-020-03941-1. Epub 2020 Oct 24.
Human papillomavirus (HPV) infection is related to cancer growth of vaginal, cervical, vulva, penile, anogenital, and non-genital oropharyngeal sites. HPV, as a sexually transmitted virus, infects all sexes similarly but with more significant pathological risks in women. This accounts for high mortality due to late detection and poor prognosis. The initial development and eventual progress of this cancer type depend entirely on three main oncogenes E5, E6 and E7, constitutively expressed to lead to carcinogenesis. Despite an opportunity for pharmacological therapy, there is still a shortage of medical treatment that may remove HPV from infected lesions. This study offers a concise summary of the nature of the issue and the current status of work on potential lead molecules and therapeutic approaches that show the capacity of HPV therapies to counteract the roles of deregulation of E5, E6, and E7.
人乳头瘤病毒（HPV）感染与阴道、宫颈、外阴、阴茎、肛门生殖器和非生殖器口咽部位的癌症生长有关。HPV 作为一种性传播病毒，在所有性别中感染的情况相似，但女性的病理风险更高。这导致了由于检测晚和预后差而导致的高死亡率。这种癌症类型的最初发展和最终进展完全取决于三个主要的致癌基因 E5、E6 和 E7，它们持续表达导致癌变。尽管有机会进行药物治疗，但仍然缺乏可以从感染病变中去除 HPV 的医疗方法。本研究简要总结了该问题的性质以及针对潜在先导分子和治疗方法的研究现状，这些方法显示了 HPV 疗法对抗 E5、E6 和 E7 失调的作用的潜力。
